Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
In pharma applications, consistent sampling and testing nomenclature is critical for data integrity and compliance with specifications and regulatory standards. Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.
Guidance documents within the pharma industry and other regulated sectors, however, offer conflicting information. This review of regulatory and compendial standards reveals the scope of the problem.
This article provides a review of available analytical nomenclature, recommended naming for individual steps, and terms used in the process flows. Part two of this paper proposes a simplified approach for sampling and testing nomenclature.
Read this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.
Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.
Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 23–33
When referring to this article, please cite it as C. Burgess, “Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).
UK Medicines Manufacturing Skills Centre Stresses Skill Development after Budget Announcement
November 8th 2024A £520 million investment for manufacturing capacity was announced by Chancellor of the Exchequer, Rachel Reeves, but academic and industry leaders stress the money should be used to train personnel.